eli lilly zepbound - Search News

News

Lilly will offer higher doses of Zepbound

Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.

Reuters on MSN · 1d

Lilly to offer highest doses of weight-loss drug Zepbound on website

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

STAT · 21h

Lilly adds highest Zepbound doses to DTC offering

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus a CVR potentially worth another $300 million.

Lilly to buy gene-editing partner Verve

The Boston Globe · 22h

Eli Lilly to buy gene-editing biotech Verve for $1.3 billion

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering better commercial prospects.

The Motley Fool on MSN · 16d

Could Viking Therapeutics Become the Next Eli Lilly?

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete with Eli Lilly's Zepbound.

U.S. News & World Report · 1d

Eli Lilly to Acquire Gene-Editing Therapy Developer Verve Therapeutics for up to $1.3 Billion, Companies Say

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru;

52mon MSN

Scholar Rock's drug helps patients on Zepbound preserve muscle in trial

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

17h

Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

7don MSN

Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Lilly’s experimental obesity drug shows promise in early study

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

5don MSN

Down 12%, Should You Buy the Dip on Eli Lilly?

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Becker's Hospital Review6d

Eli Lilly tightens rules for telehealth partners

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

5don MSN

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results